- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- Total Voting Rights
- Approval for ACCRUFeR in China expected in Q1 2026
- Q4 2025 Trading Update
- Block listing 6 Monthly Return
- FDA approves extension for ACCRUFeR®
- Block Listing Application
- Shield Wins Gold at Titan Branding Awards
- Amends Senior Secured Debt Financing
- Initiation of a Phase II Clinical Trial in Japan
- ACCRUFeR Pediatric PK Results to be Presented
More ▼
Key statistics
On Friday, Shield Therapeutics PLC (STX:LSE) closed at 9.60, -23.20% below its 52-week high of 12.50, set on Jan 16, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 10.00 |
|---|---|
| High | 10.00 |
| Low | 9.60 |
| Bid | 9.00 |
| Offer | 10.50 |
| Previous close | 10.00 |
| Average volume | 2.41m |
|---|---|
| Shares outstanding | 1.07bn |
| Free float | 304.54m |
| P/E (TTM) | -- |
| Market cap | 101.90m GBP |
| EPS (TTM) | -0.0177 GBP |
Data delayed at least 20 minutes, as of Feb 06 2026 16:01 GMT.
More ▼
